| Gene symbol | BCL2 | Synonyms | Bcl-2, PPP1R50 | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | BCL2 apoptosis regulator | ||||
| GTO ID | GTC0015 |
| Trial ID | NCT00085228 |
| Disease | Prostate Cancer |
| Altered gene | Bcl-2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Genasense|G3139|oblimersen sodium |
| Co-treatment | docetaxel |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | Randomized Phase II Trial of Docetaxel (Taxotere) and Oblimersen (Antisense Oligonucleotide Directed to BCL-2) Versus Taxotere Alone in Patients With Hormone-Refractory Prostate Cancer |
| Year | 2004 |
| Country | Austria|Belgium|Denmark|France|Israel|Italy|Netherlands|Poland|Portugal|Spain|United Kingdom |
| Company sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Other ID(s) | EORTC-30021|EORTC-30021|AVENTIS-AVE3139E/2501 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||
|
|||||||||||||